日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Efficacy and safety of anti-LAG-3 IBI110 in combination with sintilimab and chemotherapy for advanced squamous non-small cell lung cancer: a randomized phase II study

抗LAG-3抗体IBI110联合信迪利单抗和化疗治疗晚期鳞状非小细胞肺癌的疗效和安全性:一项随机II期研究

Wang, Qianyi; Xiong, Anwen; Mao, Chenyu; Wang, Wenxiang; Cui, Jiuwei; Fang, Jian; Zhuang, Wu; Yang, Kunyu; Zuo, Wei; Yang, Jun; Ye, Lika; Zhang, Zhiye; Sheng, Zengmei; Liu, Zhe; Wang, Donglin; Du, Xiaobo; Yi, Tienan; Long, Sixiang; Xu, Nong; Zhou, Caicun

A combined strategy of EGFR-MET bispecific antibody and HER3 ADC to overcome osimertinib resistance in NSCLC.

采用 EGFR-MET 双特异性抗体和 HER3 ADC 联合策略克服 NSCLC 中的奥希替尼耐药性。

Wang Yuanyuan, Guo Haoyue, Han Ruoshuang, Wu Yuhan, He Taiping, Diao Meng, Xiong Anwen, Zhou Fei, Cheng Lei, Zhao Chao, Li Xuefei, Zhou Caicun

Five-year outcomes of pembrolizumab versus chemotherapy in Chinese patients with non-small-cell lung cancer and programmed cell death ligand 1 tumor proportion score ≥1%: KEYNOTE-042 China study

帕博利珠单抗与化疗治疗中国非小细胞肺癌且程序性死亡配体1肿瘤比例评分≥1%患者的五年疗效:KEYNOTE-042中国研究

Wu, Yi-Long; Zhang, Li; Fan, Yun; Zhou, JianYing; Zhang, Li; Zhou, Qing; Li, Wei; Hu, ChengPing; Chen, GongYan; Zhang, Xin; Zhou, CaiCun; Arenas, Carmen González; Chen, Zhenghong; Yu, Wen Cheng; Mok, Tony S K

Plain language summary: comparing ivonescimab with pembrolizumab in people with PD-L1-positive non-small cell lung cancer in the HARMONi-2 study

简明语言摘要:HARMONi-2 研究中 ivonescimab 与 pembrolizumab 在 PD-L1 阳性非小细胞肺癌患者中的比较

Wang, Lei; Yao, Wenxiu; Shen, Hong; Xie, Conghua; Chen, Hualin; Chen, Kai; Su, Wenzhong; Gan, Xin; Zhuo, Minglei; Chen, Enguo; Xu, Zhi; Zhang, Yan; Wang, Mengzhao; Ma, Rui; Wu, Hongcheng; Zhang, Zhihong; Ye, Feng; Moore, Amy C; Zhou, Caicun

Atezolizumab plus bevacizumab and chemotherapy in metastatic nonsquamous NSCLC: the randomized double-blind phase 3 IMpower151 trial

阿特珠单抗联合贝伐珠单抗和化疗治疗转移性非鳞状非小细胞肺癌:随机双盲3期IMpower151试验

Zhou, Caicun; Dong, Xiaorong; Chen, Gongyan; Wang, Zhehai; Wu, Xianghua; Yao, Yu; Zhang, Yiping; Cheng, Ying; Pan, Hongming; Zhang, Xiaodong; Cui, Jiuwei; Wang, Lifeng; Chen, Xi; Li, Xiaoling; Wang, Ziping; Wang, Qiming; He, Jianxing; Wang, Mengzhao; Yan, Iris; Qian, Li; Xu, Miao; Huang, Xiayu; Sun, Chun; Cai, Jun; Wu, Qiong; Ballinger, Marcus; Kaul, Monika; Srivastava, Minu K

Taletrectinib in ROS1+ Non-Small Cell Lung Cancer: TRUST

Taletrectinib 在 ROS1+ 非小细胞肺癌中的应用:TRUST

Pérol, Maurice; Li, Wei; Pennell, Nathan A; Liu, Geoffrey; Ohe, Yuichiro; De Braud, Filippo; Nagasaka, Misako; Felip, Enriqueta; Xiong, Anwen; Zhang, Yongchang; Fan, Huijie; Wang, Xicheng; Li, Shuanglian; Lai, Rose K; Ran, Feiwu; Zhang, Xianyu; Chen, Wenfeng; Bazhenova, Lyudmila; Zhou, Caicun

Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer: The Phase 3 EXTENTORCH Randomized Clinical Trial

托瑞普利单抗联合化疗作为广泛期小细胞肺癌的一线治疗:EXTENTORCH III期随机临床试验

Cheng, Ying; Zhang, Wei; Wu, Lin; Zhou, Caicun; Wang, Donglin; Xia, Bing; Bi, Minghong; Fu, Xiuhua; Li, Chong; Lv, Dongqing; Zhao, Yanqiu; Chen, Gongyan; Yi, Tienan; Huang, Jianan; Li, Min; Yang, Runxiang; Huang, Xiaoping; Wang, Ye; Zhang, Mingjun; Pan, Yueyin; Sun, Yilan; Hu, Sheng; Zhang, Xiqin; Zhou, Min; Fang, Jian; Jin, Faguang; Liu, Yunpeng; Li, Yinyin; Zhang, Zhihong; Hu, Jie; Liu, Laiyu; Wang, Rui; Li, Yan; Gu, Kangsheng; Ding, Cuimin; Fan, Qingxia; Zhang, Guojun; Chen, Yongxing; Jiang, Liyan; Zheng, Wei-E; Chen, Shaoshui; Huang, Cheng; Han, Zhigang; Yang, Hong; Wang, Jianfang; Wang, Baocheng; Wu, Huita; Bao, Yongxing; Li, Manxiang; Luo, Xianming; Gu, Shanshan; Yu, Wenbo; Xu, Kai; Zhang, Simo; Yu, Jianjun

Camrelizumab, an Anti-PD-1 Monoclonal Antibody, Plus Carboplatin and Nab-Paclitaxel as First-Line Setting for Extensive-Stage Small-Cell Lung Cancer: A Phase 2 Trial and Biomarker Analysis

卡瑞利珠单抗(一种抗PD-1单克隆抗体)联合卡铂和白蛋白紫杉醇一线治疗广泛期小细胞肺癌:一项II期临床试验及生物标志物分析

Yu, Jia; Cai, Deyu; Zhao, Sha; Wang, Lei; Zheng, Xinlong; Xiong, Anwen; Wang, Qi; Chen, Bin; Yang, Menghang; Li, Wei; Wang, Yan; Yuan, Jiajia; Zhao, Changhong; Shi, Wei; Zhou, Caicun; Chen, Luonan; Jiang, Tao; Chen, Xiaohui; Ren, Shengxiang

Differential expression of the MYC-Notch axis drives divergent responses to the front-line therapy in central and peripheral extensive-stage small-cell lung cancer

MYC-Notch轴的差异表达导致中枢型和周围型广泛期小细胞肺癌对一线治疗的反应不同

Luo, Libo; Xia, Rui; Mao, Shiqi; Liu, Qian; Du, He; Jiang, Tao; Yang, Shuo; Wang, Yan; Li, Wei; Zhou, Fei; Yu, Jia; Gao, Guanghui; Li, Xuefei; Zhao, Chao; Cheng, Lei; Shi, Jingyun; Chen, Xiaoxia; Zhou, Caicun; Chen, Luonan; Ren, Shengxiang; Wu, Fengying

Progress and challenges of artificial intelligence in lung cancer clinical translation

人工智能在肺癌临床转化中的进展与挑战

Zhu, Erjia; Muneer, Amgad; Zhang, Jianjun; Xia, Yang; Li, Xiaomeng; Zhou, Caicun; Heymach, John V; Wu, Jia; Le, Xiuning